Will the FDA approve baxdrostat for hard-to-control hypertension?

Prediction market on kalshi. If the FDA approves baxdrostat for hard-to-control hypertension for marketing before Aug 1, 2026, then the market resolves to Yes.

24h Volume: $41.94. Liquidity: $20.97. Resolves: 8/8/2026.